Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT02098252 En recrutement IDF

Titre

Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry (TOBAS)

Type

Interventional

Pathologie

Malformations
Malformations artérioveineuses
Hémangiome

Phase

N/A

Promoteur

Centre hospitalier de l'Université de Montréal (CHUM) (Voir sur ClinicalTrials)

Date de début

mai 2014

Date de fin

janvier 2036

Dernière mise à jour

16 août 2024

Résumé

The objectives of this study and registry are to offer the best management possible for patients with brain arteriovenous malformations (AVMs) (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination) or conservative management. The trial has been designed to test a) whether medical management or interventional therapy will reduce the risk of death or debilitating stroke (due to hemorrhage or infarction) by an absolute magnitude of about 15% (over 10 years) for unruptured AVMs (from 30% to 15%); and, b) to test if endovascular treatment can improve the safety and efficacy of surgery or radiation therapy by at least 10% (80% to 90%). As for the nested trial on the role of embolization in the treatment of Brain AVMs by other means: the pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the number of treatment failures from 20% to 10%. In addition,embolization of cerebral AVMs can be accomplished with an acceptable risk, defined as permanent disabling neurological complications of 8%.

Détail

Voir le détail Intracranial arteriovenous malformations (AVMs) are relatively uncommon but increasingly discovered lesions that can lead to significant neurological disability or death.1 Population-based data suggest that the annual incidence of discovery of a symptomatic AVM is approximately 1.1 per 100 000 population.7. AVMs commonly present following an intracranial hemorrhage or seizure, although with contemporary brain imaging techniques, an increasing number of incidental lesions are found.2 Intracranial AVMs are typically diagnosed before the age of 40 years old, with more than 50% of patients presenting following an intracranial hemorrhage, the most feared sequelae of harbouring an AVM.3 An AVM-related seizure is reported as the presenting feature in 20-25% of cases4, 5 and although these can sometimes be successfully managed with anti-epileptic agents, some AVMs lead to intractable seizures in spite of medication. Other presentations include headaches, focal neurological deficits, or pulsatile tinnitus.1 The available natural history studies indicate an overall risk of initial hemorrhage of approximately 2% to 4% per year, although the long-term consequences in terms of the probability of death or long-term disability following intracranial hemorrhage remains unclear.6-8 Mortality from the first hemorrhage has been reported to occur between 10-30% of patients with a ruptured AVM, although some more recent data suggest that the mortality rate may be lower and only 10-20% of survivors have long-term disability.9-11 Hemorrhagic presentation is considered the most reliable risk factor for a repeat hemorrhage.6, 8 Unfortunately, the natural history data available is not of sufficient quality (Level V) to support making management recommendations. Over the last decade, there have been substantial developments in the management of intracranial AVMs. There has been an evolution of microsurgical as well as endovascular and radiosurgical techniques to treat these lesions. As the management options have evolved, individual and combined modality treatment protocols have been developed in different institutions for the management of AVMs. Current interventional therapy for brain arteriovenous malformations (BAVMs) is varied and includes open neurosurgical resection, radiosurgery, and endovascular management, either alone or in combination. The choice of management is largely dependent on the decisions of the local physicians that make up the treatment team, and a recent survey has demonstrated substantial variability in decision-making for almost all AVMs.12 Interventional therapies, when they are performed, are assumed to decrease the risk of initial or subsequent hemorrhage and therefore lead to better long-term outcomes, an assumption that has yet to be proven. Although the question of which AVM treatment modality is the most appropriate first choice (surgery, radiosurgery, or embolization) remains controversial, consensus can be reached in several circumstances. Surgical evacuation of a hematoma exerting significant mass effect is an uncontested appropriate management, although many patients with a hemorrhagic presentation do not necessarily meet this threshold for surgical indication. Almost all other management choices remain debatable.13, 14 A systematic review has proposed that approximately 7.1% of surgical candidates, 6.6% of endovascular candidates, and 5.1% of radiosurgical candidates were facing permanent neurological deficits after treatment.15 The epidemiological study of Davies et al, using the Nationwide Inpatient Sample (NIS) data base and surrogates such as location at discharge, showed worse outcomes for surgical and endovascular management of both ruptured and unruptured AVMs.16 Current choices of interventional therapy for brain arteriovenous malformations are varied, with decisions made on a case-by-case basis, by the local clinical team. Often these decisions will change as the results of one particular attempted treatment modality become available. All interventional therapies are performed with the assumption that they will decrease the risk of initial or subsequent hemorrhage and lead to better long-term patient outcomes. Despite these laudable goals, there is no reliable evidence that interventional management of unruptured bAVMs is beneficial, and in patients judged to need interventional therapy, such as those patients presenting with ruptures, there is no randomized evidence that embolization is beneficial. Although no clinical trial data exist on the effect of interventional therapy even after AVM hemorrhage, the most contentious issue at present is whether interventional therapy should be considered for patients with incidentally discovered AVMs, whose lesions have not bled. In patients with unruptured AVMs, the best management strategy remains unknown, and interventions should be proposed only in the context of a randomized trial. The potential role of embolization: Although endovascular AVM embolization can occasionally eradicate lesions without surgery or radiation therapy in selected cases, and although embolization may potentially improve the safety and efficacy of surgical or radiosurgical treatments in some other cases, it remains a contentious issue whether it is worth accepting the additional risks of endovascular treatment for a greater overall benefit for patients with brain AVMs that are treatable by surgery or radiation therapy. Some series have reported satisfactory results.20 It is possible that the overall morbidity and mortality of the combined interventional management strategy is increased when embolization is added to a surgical or radiosurgical procedure.17 Therefore, pre-surgical or pre-radiosurgical embolization can be offered, but only as a randomized allocation between embolization and no embolization, within the context of a trial. Primary objective: In the spirit of care trials, the primary objective of the trial and accompanying registry is to offer the best management possible for patients with brain AVMs (ruptured or unruptured) in terms of long-term outcomes, despite the presence of uncertainty. Management may include interventional therapy (neurosurgery, or radiosurgery, alone or in combination, with or without endovascular procedures, alone or combined) or conservative management. An expert multidisciplinary study group will review patients on an individual basis to determine eligibility for the trial or registry parts of the study. The trial has been designed to test whether conservative management or interventional therapy will reduce the risk of disabling stroke or death. Secondary objectives: To determine if interventional management is effective in the prevention of neurological events during 10 years. To determine the morbidity and mortality related to therapy. To follow-up and record the neurological events and the neurological status of all patients with brain AVMs recruited and managed in our institutions, regardless of management strategy chosen. Hypotheses A) Randomized comparison of interventional treatment and conservative management: Primary hypothesis: Treatment of cerebral AVMs can decrease the number of disabling neurological events caused by the presence of the AVM (excluding peri-operative complications) from 30 to 15% within 10 years. (n = 266 minima) Secondary hypothesis: Treatment of cerebral AVMs can be accomplished with an acceptable up-front risk, defined as the occurrence of a permanent disabling neurological complication in less than 15% of patients) B) Nested trial on the Role of embolization in the treatment of Brain AVMs by other means Primary hypothesis: Pre-surgical or pre-radiosurgery embolization of cerebral AVMs can decrease the number of treatment failures (failure to achieve angiographic cure) from 20% to 10% (n= 440). Secondary hypothesis: Embolization of cerebral AVMs can be accomplished with an acceptable risk, defined as permanent disabling neurological complications of 8% (3.4 to 12.6%, 95% C.I.). The study design is a prospective, multi-center, randomized, controlled trial and registry. Treatment assignment will not be masked; Interim study results will be kept confidential. The primary outcome is the composite event of death from any cause or disabling stroke (hemorrhage or infarction revealed by imaging and resulting in mRS >2). Functional outcome status will be measured by the Rankin Scale, a widely used outcome measure for stroke. The secondary measures of outcome include adverse events, ruptures, and angiographic occlusion of the lesion. Fermer le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
HOPITAL FONDATION A. DE ROTHSCHILD	Michel PIOTIN	En recrutement IDF	21/06/2024 13:32:22	Contacter
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Assistance Publique - Hôpitaux de Marseille - 13005 - Marseille - France	Pierre-Hugues Roche, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospit Régional Universitaire de Besançon - 25030 - Besançon - France	Alessandra Biondi, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Régional Universitaire de Nancy - 54035 - Nancy - France	Serge Bracard, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Régional Universitaire de Tours - 37000 - Tours - France	Denis Herbreteau, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Sainte-Anne - 75674 - Paris - France	Denis Trystram, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Bordeaux - 33000 - Bordeaux - France	Xavier Barreau, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Caen - 14033 - Caen - France	Patrick Courtheoux, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Lyon - 69002 - Lyon - France	Isabelle Pelissou-Guyotat, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Montpellier - 34000 - Montpellier - France	Vincent Costalat, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Nantes - 44093 - Nantes - France	Hubert Desal, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Rennes - 35033 - Rennes - France	Xavier Morandi, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire de Toulouse - 70034 - Toulouse - France	Christophe Cognard, MD	En recrutement		Contact (sur clinicalTrials)
Centre Hospitalier Universitaire Hôpitaux de Rouen - 76130 - Rouen - France	Christine Papagiannaki, MD	En recrutement		Contact (sur clinicalTrials)
CHRU de Brest (Brest University Hospital) - 29609 - Brest - Bretagne - France	Elsa Magro, MD	En recrutement		Contact (sur clinicalTrials)
CHU Clermont-Ferrand - Clermont-Ferrand - France	Emmanuel Chabert, MD	En recrutement		Contact (sur clinicalTrials)
CHU Dijon Bourgogne - Dijon - France	Frédéric Ricolfi, MD	En recrutement		Contact (sur clinicalTrials)
CHU Limoges - 87042 - Limoges - France	Charble Mounayer, MD	En recrutement		Contact (sur clinicalTrials)
Hôpital Bicêtre AP-HP - 94270 - Le Kremlin-Bicêtre - France	Laurent Spelle, MD	En recrutement		Contact (sur clinicalTrials)
Hôpital Universitaire Pitié-Salpêtrière - 75013 - Paris - France	Philippe Cornu, MD	En recrutement		Contact (sur clinicalTrials)
Les Hôpitaux Universitaires de Strasbourg - 67200 - Strasbourg - France	François Proust, MD	En recrutement		Contact (sur clinicalTrials)

Critères

Genre

Tous

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

- Any patient with a brain AVM

Critère de non inclusion

- Hemorrhagic presentation with mass effect requiring surgical management. In these
cases, if a residual AVM is found after the initial surgery, the patient could then
be a candidate for TOBAS.

NCT02098252 - Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry (TOBAS)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut